Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma (NCT01849263)
Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies how well ibrutinib works in treating patients with follicular lymphoma that has come back after a period of improvement or does not respond to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic in Arizona — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Mayo Clinic in Arizona — Scottsdale, Arizona
- Mayo Clinic in Florida — Jacksonville, Florida
- Mayo Clinic in Rochester — Rochester, Minnesota
- Metro Minnesota Community Oncology Research Consortium — Saint Louis Park, Minnesota
- Park Nicollet Clinic - Saint Louis Park — Saint Louis Park, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
- Juravinski Cancer Centre at Hamilton Health Sciences — Hamilton, Ontario
- Kingston Health Sciences Centre — Kingston, Ontario
- University Health Network-Princess Margaret Hospital — Toronto, Ontario
- National University Hospital Singapore — Singapore,
- National Cancer Centre Singapore — Singapore,
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Grade 3a Follicular Lymphoma
Explore by condition: All Grade 3a Follicular Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.